HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

eicosapentaenoate-lipoate

Also Known As:

EPA-LA; EPA-TA

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kumar, Sekar Ashok: 3 articles (11/2006 - 05/2005)
2.	Sudhahar, Varatharajan: 3 articles (11/2006 - 05/2005)
3.	Varalakshmi, Palaninathan: 3 articles (11/2006 - 05/2005)
4.	Baba Ahmed, F Z: 1 article (06/2016)
5.	Bouanane, S: 1 article (06/2016)
6.	Merzouk, H: 1 article (06/2016)
7.	Soufi, N: 1 article (06/2016)
8.	Lenin, M: 1 article (11/2001)
9.	Nagaraj, M: 1 article (11/2001)
10.	Thiagarajan, A: 1 article (11/2001)

Related Diseases

1.	Body Weight (Weight, Body) 07/01/2006 - "Among them, 3 groups of rats were treated with either EPA (35 mg/kg body weight/day, oral gavage), LA (20 mg/kg body weight/day, oral gavage) or EPA-LA derivative (50 mg/kg body weight/day, oral gavage) from 16th day to 30th day of the experimental period. " 05/01/2005 - "Of these groups, 3 groups of rats were treated with either EPA (oral gavage, 35 mg/kg body weight/day), LA (oral gavage, 20 mg/kg body weight/day) or EPA-LA derivative (oral gavage, 50 mg/kg body weight/day) from 16th day to 30th day of the experimental period. " 11/01/2006 - "Eight groups of male Wistar rats were employed in this study, wherein four groups were fed with a high cholesterol diet (rat chow supplemented with 4% cholesterol and 1% cholic acid; HCD) for 30 days, among which, three groups of rats were also treated with either EPA (35 mg/kg body weight/day, oral gavage), LA (20 mg/kg body weight/day, oral gavage) or EPA-LA derivative (50 mg/kg body weight/day, oral gavage) commencing from 16th day of the experimental period. "
2.	Atherosclerosis 11/01/2006 - "Protective role of eicosapentaenoate-lipoate (EPA-LA) derivative in combating oxidative hepatocellular injury in hypercholesterolemic atherogenesis." 07/01/2006 - "Oxidative renal injury and lipoprotein oxidation in hypercholesterolemic atherogenesis: Role of eicosapentaenoate-lipoate (EPA-LA) derivative."
3.	Placenta Accreta 01/01/2020 - "En comparación con el grupo de pacientes sin indicios de ultrasonido de algún trastorno del EPA, la presencia de al menos un indicio ecográfico típico de trastorno del EPA en combinación con EIC tuvo una RMD de 217,2 (IC 95%, 27,7-1703,4; P<0,001) para la placenta percreta y de 687,4 (IC 95%, 121,4-3893,0; P<0,001) para la histerectomía por cesárea. "
4.	Hypertension (High Blood Pressure) 06/01/2016 - "T cells are isolated from the blood of the control and obese women with hypertension the University Hospital of Tlemcen (Algeria), these cells are incubated in the presence of a synthetic mixture of PUFA to 30μM (DHA/EPA/LA) and stimulated by mitogens for 48hours. "
5.	Hypercholesterolemia 05/01/2005 - "Attenuation of serum lipid abnormalities and cardiac oxidative stress by eicosapentaenoate-lipoate (EPA-LA) derivative in experimental hypercholesterolemia."

Related Drugs and Biologics

1.	Cholic Acid
2.	Cholesterol
3.	eicosapentaenoate-lipoate
4.	Mitogens
5.	Lipoproteins (Lipoprotein)
6.	Lipids